托伐普坦治疗常染色体显性多囊肾病的使用更新:代表ERA遗传性肾病工作组、欧洲罕见肾病参考网络和多囊肾病国际的共识声明
该共识声明基于TEMPO 3:4和REPRISE两项随机临床试验及事后分析,更新了托伐普坦治疗常染色体显性多囊肾病(ADPKD)的患者选择算法,并提供实践建议,强调仅对快速进展患者启动治疗。
要点
- 托伐普坦是血管加压素V2受体拮抗剂,基于TEMPO 3:4试验获批用于ADPKD。
- REPRISE试验提供了托伐普坦用于晚期疾病的重要证据。
- 更新算法指导快速进展ADPKD患者的托伐普坦选择。
核心结论
- 提供更新的算法以指导托伐普坦治疗的患者选择,并补充实践建议。
研究设计与样本
- 欧洲肾脏协会(ERA)遗传性肾病工作组、欧洲罕见肾病参考网络和多囊肾病国际代表制定的共识声明。
主要发现
- TEMPO 3:4试验是托伐普坦获批的里程碑试验。
- REPRISE是第二项随机临床试验,评估托伐普坦在晚期疾病中的使用。
- 两项随机临床试验的事后研究增加了重要证据。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Approval of the vasopressin V2 receptor antagonist tolvaptan-based on the landmark TEMPO 3:4 trial-marked a transformation in the management of autosomal dominant polycystic kidney disease (ADPKD). This development has advanced patient care in ADPKD from general measures to prevent progression of chronic kidney disease to targeting disease-specific mechanisms. However, considering the long-term nature of this treatment, as well as potential side effects, evidence-based approaches to initiate treatment only in patients with rapidly progressing disease are crucial. In 2016, the position statement issued by the European Renal Association (ERA) was the first society-based recommendation on the use of tolvaptan and has served as a widely used decision-making tool for nephrologists. Since then, considerable practical experience regarding the use of tolvaptan in ADPKD has accumulated. More importantly, additional data from REPRISE, a second randomized clinical trial (RCT) examining the use of tolvaptan in later-stage disease, have added important evidence to the field, as have post hoc studies of these RCTs. To incorporate this new knowledge, we provide an updated algorithm to guide patient selection for treatment with tolvaptan and add practical advice for its use.
引用
- Müller RU, Messchendorp AL, Birn H, et al. An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International. Nephrol Dial Transplant. 2022. PMID: 35134221. doi:10.1093/ndt/gfab312
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。